5 Followers on Owler

SynAffix

SynAffix develops ligation methodologies and conjugation chemistry. Read more

Peter van de Sande's photo - CEO of SynAffix

CEO

Peter van de Sande

CEO Approval Rating

70/100

Founded:

06/2010

Status:

PrivateIndependent Company

Est. Annual Revenue
Est. Employees
Sector

Update Industry
Headquarters

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $27.3M a good estimate for SynAffix's revenue?

SynAffix Acquisitions

No recent acquisitions found related to SynAffix

SynAffix Funding History

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Feb 2014
--

Aravis

Since SynAffix was founded in 06/2010, it has participated in 1 round of funding. In total SynAffix has raised $0. SynAffix's funding round was on Feb 2014 for a total of $0

SynAffix Investments

No recent investments found related to SynAffix

SynAffix News

July 23, 2020The Pharma Letter

Synaffix collaboration with ADC Therapeutics expanded

Dutch biotech firm Synaffix today announced that Swiss oncology-focused drug discovery firm ADC Thera... See more »
January 7, 2020The Pharma Letter

More dealmaking for Netherlands-based Synaffix

Dutch antibody-drug conjugate (ADC) specialist Synaffix and Shanghai Miracogen have expanded an exist... See more »
January 7, 2020BioPortfolio

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate.

Expansion of existing deal with leading Chinese ADC developer Total of six partnered ADCs based on Sy... See more »
July 23, 2019Contract Pharma

Abzena Completes ADC Tech Transfer

Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client project... See more »
May 29, 2019BioPortfolio

ADC Therapeutics Expands to Third Program Using Synaffixs ADC Platform under Existing Agreement.

AMSTERDAM NETHERLANDS - May 28 2019 - Synaffix B.V. a Dutch biotechnology company focused on the adva... See more »
April 12, 2019Pharmabiz

Shanghai Miracogen gets non─exclusive rights to Synaffix's proprietary GlycoConnect & HydraSpace ADC technologies for use in its next clinical candidate

Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clin... See more »
April 12, 2019Biospectrum Asia

Synaffix announces license agreement with Miracogen worth $125M

Miracogen will be responsible for the research, development, manufacturing and commercialization of t... See more »

SynAffix Press Releases

March 5, 2015BUSINESS WIRE

SynAffix BV to Present Latest Advancement in Antibody-Drug Conjugate Technology at the 9th Annual BIO Europe Spring Conference in Paris

OSS, Netherlands--(BUSINESS WIRE)--SynAffix BV, a biotechnology company exclusively focused on the de... See more »

Social Media

SynAffix Headquarters

Kloosterstraat 9

Oss, Noord-Brabant5349

31-88-022-4505

Driving Directions »

Trending Companies

SynAffix Summary

ABOUT

Overview

SynAffix develops ligation methodologies and conjugation chemistry. SynAffix was founded in 06/2010. SynAffix's headquarters is located in Oss, Noord-Brabant, NL 5349. It has raised undisclosed amount in 1 round. The latest round was in Feb 2014. Some...

CEO

SynAffix's CEO, Peter van de Sande, currently has an approval rating of 70%. SynAffix's primary competitors are

Frequently Asked Questions about SynAffix

  1. When was SynAffix founded?

    SynAffix was founded in 06/2010
  2. Who is SynAffix's CEO?

    SynAffix's CEO is Peter van de Sande
  3. How much revenue does SynAffix generate?

    SynAffix generates $27.3M in revenue
  1. How much funding does SynAffix have?

    SynAffix has historically raised $0 in funding
  2. Where is SynAffix's headquarters?

    SynAffix's headquarters is in Oss Noord-Brabant, NL
  3. How many employees does SynAffix have?

    SynAffix has 392 employees